This story reports on several newer, noninvasive prenatal screening tests called cell-free DNA tests. These tests work by examining pieces of fetal DNA from a blood sample taken from the mother. Although more accurate than traditional screening tests (blood tests plus an ultrasound), the new tests are not accurate enough to provide a definitive diagnosis. This can only be obtained from a more invasive procedure such as amniocentesis. The story did a good job of explaining the confusion surrounding these new tests, which is a result of some doctors and women not understanding the tests’ limitations and accuracy levels compared with other tests. The story could have provided more numbers — including costs and false positive rates — to help readers better understand the tradeoffs involved.
The new prenatal screening tests discussed in this story are not diagnostic tests, and patients may not understand the difference between the certainty of a diagnostic test and the uncertainties of a screening test. Solid health reporting can help women understand these crucial distinctions and make better decisions. The stakes are high when women are making choices about whether to terminate or keep a pregnancy based on these results.
The story mentioned that insurance coverage of the new tests varies, but no indication of an actual dollar amount was given.
The accuracy level of the new screening tests was described as better than existing screening tests (blood tests plus ultrasound), but this benefit was not quantified (i.e., the screening tests can detect X disease Y% of the time compared with traditional tests, or false alarms occur for X% of new tests vs Y% for traditional screening tests). A linked study abstract provided this detail, but the jargon-filled text would be difficult for most readers to understand. A quick rundown of those numbers would have been easy to provide in the story itself.
The story cited several harms associated with the new screening tests, including the risk that some women may terminate a pregnancy based on the screening results alone without follow up diagnostic tests. It also noted that the tests can pick up minor genetic abnormalities that might previously have gone unnoticed.
The study cited in the article (through a hyperlink) reports that the new screening tests did a better job of detecting chromosomal abnormalities. An independent expert quoted in the story agrees that the new tests are more accurate than traditional screening tests. The story’s bottom-line take on the evidence seems appropriate.
The story sought out several expert sources for their opinions about the testing, and it appropriately noted that one of these sources (Dr. Lee Shulman) is a consultant to firms selling the new screening tests. However, it failed to note that another of these expert sources (Dr. Diana Bianchi) was also a paid consultant to a testing company. In addition, it didn’t caution readers that the study the story links to was paid for by a testing company.
The story did compare and contrast the new prenatal screening tests to traditional diagnostic tests like amniocentesis and chorionic villus sampling, which are more invasive.
The story mentioned the tests were new to the market (available since 2011), and that many doctors were still not familiar with them. The story made it clear that these tests were not regulated by the FDA.
The story discussed how this type of prenatal testing differs from traditional testing and emphasized that the tests were so new that their usefulness and limitations were not clearly understood.
The story does not appear to rely on a news release. The reporter clearly spoke to several expert sources.
Systematic, Criteria-Driven
A week like this should teach you how/what to ignore: #COVID19 news & PR about studies in monkeys & mice...about studies of dishonesty & BMI…and about rating attractiveness of women with endometriosis!!! https://www.healthnewsreview.org/2020/08/crazy-week-of-pr-news-on-studies-should-teach-us-how-what-to-ignore/
“to project certainty where it simply does not exist is communication malpractice at a time like this and with a public health issue like this.” @garyschwitzer on @ContentScience https://review.content-science.com/covering-covid-19-vaccine-news-part-two-from-the-publisher-of-health-news-review/
In case you weren't aware: Prestigious journalism organizations and outlets take money from pharma, @garyschwitzer https://www.healthnewsreview.org/2020/08/drug-company-influence-on-journalism/#.XyrYGZeNvXA.twitter @HealthNewsRevu
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like